Brokerages expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will post earnings per share (EPS) of ($1.29) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Five Prime Therapeutics’ earnings. The lowest EPS estimate is ($1.51) and the highest is ($1.04). Five Prime Therapeutics reported earnings per share of ($0.73) in the same quarter last year, which indicates a negative year-over-year growth rate of 76.7%. The company is expected to issue its next earnings report after the market closes on Tuesday, February 27th.
On average, analysts expect that Five Prime Therapeutics will report full-year earnings of ($5.56) per share for the current fiscal year, with EPS estimates ranging from ($5.84) to ($5.38). For the next fiscal year, analysts forecast that the firm will report earnings of ($5.00) per share, with EPS estimates ranging from ($6.65) to ($3.23). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Five Prime Therapeutics.
Several research analysts recently weighed in on FPRX shares. Royal Bank of Canada boosted their price objective on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. BMO Capital Markets boosted their price objective on shares of Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. ValuEngine cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Zacks Investment Research cut shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, BidaskClub cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Three investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $64.00.
Five Prime Therapeutics (FPRX) traded up $0.51 during mid-day trading on Tuesday, reaching $18.20. 491,605 shares of the company traded hands, compared to its average volume of 588,803. Five Prime Therapeutics has a 1 year low of $17.01 and a 1 year high of $49.30. The company has a market cap of $618.99, a PE ratio of -3.59 and a beta of 3.56.
TRADEMARK VIOLATION WARNING: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3222041/brokerages-anticipate-five-prime-therapeutics-inc-fprx-will-post-earnings-of-1-29-per-share.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.